CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 335 enrolled
Drug / intervention
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03966911
NCT03966911N/ACompleted

Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics

Medtronic MiniMed, Inc.·interventional·Posted May 29, 2019·Updated Jun 7, 2021

In Brief

A clinical study evaluating Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter for Type 1 Diabetes Mellitus and Type2 Diabetes Mellitus. Completed, enrolled 335 participants across 15 sites.

Detailed Summary

The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 29, 2019
Enrollment StartJun 14, 2019
Primary CompletionMay 13, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.1 years ago

Interventions

Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitterdevice

Continuous Glucose Monitoring and frequent sample testing